Laura Magnano

Hospital Clínic de Barcelona — Spain

Medicine · Health Sciences

25h-index2.1kcitations175works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(105), Chronic Lymphocytic Leukemia Research(54), Viral-associated cancers and disorders(33), CAR-T cell therapy research(26), Ovarian cancer diagnosis and treatment(19)

Publications173 total

A step forward in the treatment of relapsed or refractory follicular lymphoma
The Lancet·2025
Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience
Blood·2025
Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma
Blood·2025Open Access
Autologous and allogeneic stem cell transplantation for ALK-positive anaplastic large cell lymphoma: An analysis of the EBMT lymphoma working party
Blood·2025Open Access
First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO)
Blood·2025
Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report
International Journal of Molecular Sciences·2025· 3 citedOpen Access
Efficacy and safety of the academic anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma
HemaSphere·2025· 1 citedOpen Access
Epidemiological shifts of invasive fungal infections in the current era of haematology
Medical Mycology·2025· 2 cited
203 | CHARACTERIZATION AND CLINICAL IMPACT OF THE CIRCULATING IMMUNE CELL PROFILE IN PATIENTS WITH FOLLICULAR LYMPHOMA
Hematological Oncology·2025Open Access
595 | HISTOLOGICAL TRANSFORMATION IN MARGINAL ZONE LYMPHOMA (MALT, NODAL AND SPLENIC): RISK, CLINICAL FEATURES AND OUTCOME
Hematological Oncology·2025Open Access
523 | CORRELATION OF BASELINE PET/CT IMAGING AND MOLECULAR FEATURES WITH CLINICAL OUTCOMES IN A POPULATION‐BASED MCL STUDY
Hematological Oncology·2025Open Access
341 | IBRUTINIB FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LARGE B‐CELL LYMPHOMAS: EXPERIENCE FROM THE GELTAMO GROUP
Hematological Oncology·2025Open Access
104 | A GLOBAL PHASE 1B STUDY OF JNJ‐90014496, A CD19/CD20 BI‐SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY, IN RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL)
Hematological Oncology·2025Open Access
YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2Y641mut germinal center-derived lymphoma
Neoplasia·2025· 4 citedOpen Access
Ypel2 Regulates the Efficacy of Brd4-Ezh2 Dual Targeting in Ezh2y641mut Germinal Center-Derived Lymphoma
SSRN Electronic Journal·2025Open Access
Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma”
Annals of Oncology·2024· 2 cited
Utility of Baseline PET/CT As Surrogate of Molecular Features in Mantle Cell Lymphoma
Blood·2024
CD70 Deregulation in Follicular Lymphoma at Diagnosis Is Associated with Relapse and Opens New Avenues for Dual CD19-CD70 CAR-T Therapy
Blood·2024
Hairy cell leukemia with an atypical extranodal presentation: A clinicopathological analysis of four cases
Human Pathology·2024
CLL-573 Characterization and Outcomes of the Spanish Patients Included in the GLOW and CAPTIVATE-FD Studies: Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Clinical Lymphoma Myeloma & Leukemia·2024
page 1 of 9Next →

Frequent Co-authors

Armando López‐Guillermo(23), Elı́as Campo(22), Eva Giné(20), Julio Delgado(20), Alfredo Rivas‐Delgado(15), Neus Villamor(15), Ferran Nadeu(12), Olga Balagué(12), Pablo Mozas(11), Carlos Fernández de Larrea(10), Iván Dlouhy(9), Tycho Baumann(9), Dolors Colomer(9), Andrea Rivero(9), Jordina Rovira(8), Ana Jiménez Ubieto(8), Silvana Novelli(8), Laura Rosiñol(8), Blanca González‐Farré(7), Santiago Mercadal(7)